Catalent Increases Sterile Fill/Finish Capacity

Catalent Pharma Solutions has completed the construction of its newly renovated 3,300-sq.-ft. aseptic fill-finish manufacturing facility at Research Triangle Park, NC.
 
Catalent now offers comprehensive sterile product formulation and development services at the site, including preformulation, formulation development, process development and manufacturing support, as well as full service analytical development and stability capabilities.
 
The sterile clinical manufacturing suite will provide Class A manufacturing space containing a flexible aseptic vial filling line capable of producing Phase I and Phase II clinical trial materials that comply with global GMP requirements.
 
“This renovation is part of Catalent’s ongoing investment to provide integrated solutions to meet biologic and biosimilar drug development companies’ growing needs,” said Christine Dolan, vice president and general manager of Catalent’s Development and Analytical Solutions business. “Combined with Catalent’s GPEx technology, expert biopharmaceutical lab services capabilities, world leading clinical trial supply services and commercial manufacturing capabilities, we will be able to help our customers bring more products from gene to market.”